(ECNS) -- China's first domestic COVID-19 oral medicine Azvudine is now covered by medical insurance.
It has been included in the COVID treatment plan by the National Health Commission since August 9.
All drugs that have been included in the treatment plan can be temporarily paid for by medical insurance, said the National Healthcare Security Administration.
Azvudine, produced by Genuine Biotech Limited, a company based in Henan Province, contains 35 tablets per bottle with one milligram per tablet. Its price was set at less than 300 yuan (about $44.4) per bottle.